ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Aligos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.84−0.02 (-0.41%)
Close on Oct 19, 2026
- Market cap
- $50.49M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$5.15 (−51.55%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Aligos Therapeutics, Inc. grew revenue 19.4% to $3.74M over the twelve months to Jun 30, 2026.
Revenue
$3.74M
+19.4% vs. a year earlier
Operating income
-$78.99M
TTM Q2 2026
EPS, diluted
-$2.45
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $50.49M
- P/E ratio
- –
- Price to sales
- 13.50
- Price to book
- 1.58
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.74M
- Net income
- -$75.96M
- EPS, diluted
- -$2.45
- Book value per share
- $3.06
- Diluted shares
- 10M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
$3.74M+19.4% YoY
Operating income
-$78.99M
Net income
-$75.96M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months